Review

Local Treatment of Burns with Cell-Based Therapies Tested in Clinical Studies

Anna Paulina Domaszewska-Szostek 1,*, Marta Olga Krzyżanowska 2, Anna Maria Czarnecka 3 and Maria Siemionow 4

1 Department of Human Epigenetics, Mossakowski Medical Research Centre, Polish Academy of Sciences, 5 Pawińska St, 02-106 Warsaw, Poland
2 Division of Ophthalmology and Optometry, Department of Ophthalmology, Collegium Medicum, Nicolaus Copernicus University, 85-067 Bydgoszcz, Poland; marta.krzyz@gmail.com
3 Department of Neurotoxicology, Mossakowski Medical Research Centre, Polish Academy of Sciences, 5 Pawińska Street, 02-106 Warsaw, Poland; aczarnecka@imdik.pan.pl
4 Department of Orthopaedics MC 944, University of Illinois at Chicago, 900 South Ashland Avenue, 3356 MCBRB, Chicago, IL 60607, USA; siemiom@uic.edu
* Correspondence: adomaszewska@imdik.pan.pl; Tel.: +48-22-6086404

Abstract: Effective wound management is an important determinant of the survival and prognosis of patients with severe burns. Thus, novel techniques for timely and full closure of full-thickness burn wounds are urgently needed. The purpose of this review is to present the current state of knowledge on the local treatment of burn wounds (distinguishing radiation injury from other types of burns) with the application of cellular therapies conducted in clinical studies. PubMed search engine and ClinicalTrials.gov were used to analyze the available data. The analysis covered 49 articles, assessing the use of keratinocytes (30), keratinocytes and fibroblasts (6), fibroblasts (2), bone marrow-derived cells (8), and adipose tissue cells (3). Studies on the cell-based products that are commercially available (Epicel®, Keraheal™, ReCell®, JACE, Biobrane®) were also included, with the majority of reports found on autologous and allogeneic keratinocytes. Promising data demonstrate the effectiveness of various cell-based therapies; however, there are still scientific and technical issues that need to be solved before cell therapies become standard of care. Further evidence is required to demonstrate the clinical efficacy and safety of cell-based therapies in burns. In particular, comparative studies with long-term follow-up are critical.

Keywords: burns; radiation burns; keratinocytes; fibroblasts; mesenchymal stem cells; adipose tissue

1. Background

Burns represent a substantial public health problem worldwide. According to the World Health Organization, there are approximately 265,000 deaths each year due to fires, electric burns, and chemical substances [1]. Furthermore, over 96% of fatal fire-related burns occur in low- and middle-income countries [1]. Thermal burns are the most common type of burn injuries, making up about 86% of the burned patients requiring burn center admission [2]. The burn depth is proportional to the temperature of the causative agent and the contact time length [3]. Effective wound management is a major challenge and an important determinant in patients’ survival and prognosis with severe burns.

Burn wounds are characterized by loss of progenitor cell population that is necessary for the epidermis and dermis regeneration [4]. Severe burns would benefit from cell therapy by enhancing wound healing, replacement, and regeneration of damaged skin. A significant challenge is incorporating skin appendages, reducing fibrosis and inflammation [5]. Furthermore, by destroying the epidermis, the likelihood of bacterial infection increases [6].

We decided to separate cell therapy application in radiation burns from other types of burns in our review (Figure 1). Although a radiation injury is often referred to as a
“burn”, the development of the injury is considerably different from that of a thermal or chemical burn [7]. Unlike chemical or thermal skin injuries, the lesions caused by radiation exposures do not appear for hours to days following exposure [8]. Possible harmful side effects of radiotherapy to surrounding healthy tissues often lead to necrosis [9]. Irradiation can also hinder wound healing, leading to chronic ulceration. It impairs proliferation, differentiation, and secretion of extracellular matrix proteins and growth factors. Besides, the presence of reactive oxygen species can lead to dysregulated myofibroblast production, resulting in abnormal collagen production. Wound healing impairment by inhibiting inflammatory cells and angiogenesis is known as radiation-induced fibrosis, a characteristic feature of delayed radiation injury [10]. To date, there is no standardized treatment for chronic radiation-induced wounds. Due to the observed constant inflammation, both at the site of injury and systemically, skin transplant failures occur. Thermal and radiation burns differ in their inflammatory response. After radiation burns, recurrent inflammation occurs, leading to erythema at the exposure site and finally necrotic wounds [11,12].

Figure 1. Cell therapy strategies for burn wound healing.

Surgical debridement followed by split-thickness skin grafting (STSG) is a standard therapy for burns. One of the biggest problems with severe burn patients is the limitation of available donor skin sites for surgical treatment, especially in cases with over 50% of total body surface area (TBSA). Thus, the technique of meshed STSG allows expanding skin grafts to a much larger size [13–15]. However, when the expansion is over 1:6 of meshed grafts, there is a lower re-epithelialization rate and a significant decrease in survival rate [13]. Moreover, STSG increases the wound’s total surface, leading to higher water and electrolyte loss from the patient’s body [16]. Another issue is donor site hypertrophic scar and contracture, especially in children due to their physical growth [17]. Re-epithelialization is crucial in the burn wound treatment, and there are many different methods of delivering skin cells to the wound bed [13,18]. Many efforts have been made towards autologous and
allogeneic cell-based therapies and skin substitutes, both as monotherapy and as a part of combined treatment.

This review aims to overview the up-to-date local treatment of burns with cellular therapies based on the published data from 1983 up to 2020. We discussed the results of clinical studies only. Practical options for future therapeutic applications of cell therapies for burns treatment and ongoing challenges associated with burn injuries are finally considered. In our previous review concerning the use of cell-based therapies in non-healing wounds, we presented the characteristics of all cell types; therefore, we did not repeat this information in this review [19].

2. Experimental Section

Study Selection

Using Pubmed search engine and ClinicalTrials.gov, we analyzed the available data concerning the use of human keratinocytes, fibroblasts, bone marrow cells, adipose tissue cells, as well as cell-based products available on the market like Epicel®, Keracea™, ReCell®, and JACE®. We have excluded all preclinical (animal) studies. A systematic literature search was conducted from 1983 to 2020 using the following terms “burns” OR “radiation burns” combined with “keratinocytes” OR “fibroblasts” OR “mesenchymal stem cells” OR “adipose tissue”. Only articles published in peer-reviewed scientific journals were included in the analysis. The analysis covered 49 English-language articles, assessing the use of keratinocytes (30), keratinocytes and fibroblasts (6), fibroblasts (2), bone marrow-derived cells (8), and adipose tissue cells (3). The patients’ characteristics include the degree of burn, age, and the length of follow-up.

3. Results

3.1. Clinical Research and Applications of Cell-Based Therapies for Burn Wound Healing

3.1.1. Autologous Keratinocytes

Autologous keratinocytes may be administered as a cultured and non-cultured cell suspension in the spray device, single-cell suspension, and in the form of cultured epithelial sheets [15]. Cultured epithelial autograft (CEA) is prepared as a sheet (25 or 50 cm²) consisting of isolated and cultured keratinocytes fixed on petrolatum gauze [15,20]. Approximately 2–3 weeks are required to prepare a confluent sheet [21]. CEA is efficient for extensive skin burns when available healthy skin is insufficient, but it is high cost and the lack of dermal substrates limits their applicability. Another disadvantage of this method is a long-term culturing period, which extends the time between biopsy and grafting. Moreover, cell culturing has other difficulties such as lack of adherence and wound contracture [22,23].

One of the pioneers in this field, Gallico et al., demonstrated that cultured autologous epithelium could be used to generate permanent epidermis on half or more of the TBSA [24]. The use of the CEA in the treatment of deep second-and third-degree burn wounds was described by Teepe et al. The authors observed that the wounds excised at an early stage showed a significantly better graft take than non-excised chronic wounds that were grafted at a later stage. The regenerated skin was smooth and pliable. Moreover, scars showed less hypertrophic formation in comparison with meshed grafts. The authors showed an inverse correlation between the graft take and the patient’s age [25]. This correlation was not confirmed by the multicenter study of Odessey et al., demonstrating that patient’s age, burn size, and extent of full-thickness injury did not significantly affect the graft’s take. The average final take was around 60%, and 22% of patients achieved a final take of ≥ 90% [26]. Another advantage of CEA transplantation in burn patients is reduced mortality. In a study by Munster et al., there was a decline in mortality from 48% to 14% [27]. Increased collagen deposition, decreased stromal cellularity, and significant effect on connective tissue phenotype and dermal neogenesis after CEA transplantation were observed by Compton et al. on a group of pediatric patients [28]. CEA may also be a part of a combined burn wounds treatment. A 15-year-retrospective study by Auxenfans
et al. revealed that it allows rapid healing of STSG donor sites and deep second-degree burns, due to the decreased wound surface and stimulated healing of the remaining wound [29]. Chrapusta et al. conducted a study on children with significantly shorter healing time when STSG and cultured autologous keratinocytes were applied in one stage [30]. In 2015 Matsumura et al. published studies on CEA treatment of patients with severe burn wounds. CEA, whose manufacturing period was between 22 and 30 days, contributed to wound closure and patients’ survival [31]. In a retrospective study by Wood et al., patients were treated with CEA in the form of a sheet, cell suspension (CellSpray), or both. After an average of 10.6 days, cell suspension could be administered compared with 25 days for cultured sheet grafts due to the faster time of the pre-confluent stage cell culture [32]. Kym et al. observed no clinical differences between the sheet and spray-type of CEA; both resulted in significantly higher patient survival than the non-CEA group [33]. Another retrospective study was published by Ciordde et al. Favorable outcome was most often associated with young age and a small number of infectious complications [34]. Chua et al. published a 12-year retrospective review of patients who received CEA. The authors compared the outcomes after STSG and micrografting, both followed by the CEA application, and observed that a significantly lower amount of skin allografts was needed in the micrografting group [35]. The comparison of CEA, Cuono’s method, and CEA combined with STSG were analyzed in a study by Lo et al. The Cuono’s method is based on the two-stage procedure. A cadaver skin allograft is grafted on a wound. After 2–3 weeks, the cadaver epidermis is removed, and CEA is applied. Sites treated with either Cuono method or CEA with initial take rates < 60% did not heal. Moreover, the highest take rate was achieved when CEA was combined with STSG [36]. The most extensive study on CEA to date was performed by Hickerson et al. The results of this analysis were compared to the patients’ outcome with comparable burns, reported in the National Burn Repository. This study’s main conclusion was that when CEA was used with STSG, the survival rate increased [37].

3.1.2. Products Based on Autologous Keratinocytes

- **Epicel®**

  Epicel® is a wound dressing composed of the patient’s autologous, proliferative keratinocytes sheets. FDA-approved indication for use in adult and pediatric patients with deep dermal or full-thickness burns comprises a total body surface area greater than or equal to 30%. It may be used in conjunction with split-thickness autografts, or alone in patients for whom split-thickness autografts may not be an option due to the severity and extent of their burns [38]. This CEA serves as a successful permanent burn coverage in severely traumatized patients. According to the FDA, Epicel® ranges from 2 to 8 cell layers thick and measures approximately 50 cm² [38]. Age is one of the factors determining the CEA’s take, as reported by Carsin et al. in a five-year, single-center study. Those younger than 15 years old presented the highest initial and final Epicel® CEA take (82.28% and 85.27%, respectively). More extensive burns tended to occur in the younger population, which contributed to these results. Surprisingly, no correlation between the take and burn wound size was observed. The authors stated that Epicel® CEA appears to have a high beneficial value in managing burns covering over > 60% of TBSA [39].

- **Keraheal™**

  Keratinocyte spray suspension is the next method for delivering epidermal cells to the wound bed. Keraheal™ is one of the products available on the market (Biosolution Co. Ltd, Seoul, Korea). Unlike the conventional sheet type, it contains mainly non-differentiated pre-confluent cells. According to the manufacturer, this spray-type autologous keratinocyte therapy is indicated for deep second-degree burns covering more than 30% of TBSA and in third-degree burns—more than 10% of TBSA [40]. Keraheal™ improved scars’ quality in severely burned patients and was effective in saving lives [12]. According to Yim
et al., Keraheal™ requires a lower number of cells to culture and shorter culturing time in comparison to the sheet type. In studies of Keraheal™ combined with meshed grafts, the CEA's take rate after four weeks was 100% in Yim’s and 68% in Lee’s study [13,41].

- **ReCell®**

ReCell® is another product applied via spray (Clinical Cell Culture, Cambridge, UK). This system uses rapid, autologous cell harvesting, processing, and delivery technology. A small sample of the patient’s skin is obtained to isolate keratinocytes, fibroblasts, and melanocytes that are sprayed over the burn wound by a special nozzle [42]. FDA-approved indication for the treatment of acute thermal burn wounds in patients 18 years of age and older. An appropriately licensed healthcare professional uses the RECELL® Device at the patient’s point-of-care to prepare autologous Regenerative Epidermal Suspension (RES™) for direct application to acute partial-thickness thermal burn wounds or application in combination with meshed autografting for acute full-thickness thermal burn wounds [43]. A randomized trial comparing results obtained with the ReCell® autologous cell harvesting (ACH) system and the classic skin grafting for epidermal replacement in the deep partial-thickness burns was performed by Gravante et al. Their study revealed that skin grafting was faster than ReCell®, but ReCell® biopsy areas and post-operative pain were smaller than in traditional grafting [44]. Not only adults received ReCell®, Wood et al. performed a randomized controlled pilot study on pediatric patients with partial-thickness scald injury. They tested if the addition of ReCell® to the Biobrane® synthetic wound dressing gave better results and compared them to the standard treatment—skin grafting [45]. According to the authors, the best outcomes can be obtained when debridement, followed by Biobrane® with or without ReCell®, is performed within four days after-burn. It leads to decreased healing time and requires fewer dressing changes. Moreover, it is less painful [45]. In another study by Sood et al., the effects of ReCell® treatment were compared to the effects after a meshed STSG. Eight patients had 100% take with both treatments, and two patients had significant non-take and graft loss. Patients benefited from the ReCell® therapy having a decreased donor site size and comparable outcomes with meshed STSG treatment [47].

- **JACE®**

JACE® is a Green-type CEA, an epidermal cell sheet supplied in cultured autologous epidermis produced from keratinocytes for treatment of severe, extensive burns. It allows obtaining cells from a small area of the patient’s tissue. These sheets are grafted onto the wound surface with preserved dermis for the closure of the wound via engraftment and epithelialization [48]. JACE® is indicated for patients with a deep-dermal or full-thickness burn wound when sufficient donor sites for autologous skin grafts are not available, and the burn area is 30% or more of the TBSA. After skin grafting, a cultured epidermal cell sheet is applied onto the reconstructed dermis [49]. The results from a 6-year multicenter study of JACE® were published by Matsumura et al. The authors demonstrated a 66% take rate at four weeks after grafting and found that the JACE® application contributed to patient survival up to seven weeks after burn [50]. Similar results were obtained by Hayashi et al., who used a combination of JACE® CEA and STSG or meshed split-thickness dermis graft, de-epithelialized STSG. A meshed dermis graft required more healing time than STSG, but it enabled covering a burn wound by collecting tissue from only a small donor site. The skin graft taken at four post-operative weeks was between 85 and 95% [48]. Clinical
applications of products based on autologous keratinocytes in burns are summarized in Table 1.

3.1.3. Autologous Engineered Skin (Keratinocytes and Fibroblasts)

Hansbrough et al. developed procedures for establishing confluent, stratified layers of cultured, autologous keratinocytes on a modified collagen-glycosaminoglycan membrane containing autologous fibroblasts. These grafts were transferred onto the areas of full-thickness burn wounds. It took up to 9 days to form the basement membrane. According to the authors, this technique offers a significant advance in extensively burned patients’ care and can also provide skin for reconstructive surgeries [51]. Boyce et al. investigated cultured skin substitutes (CSS) consisting of autologous cultured keratinocytes and fibroblasts. The cells were attached to collagen-based sponges prepared from STSG. When CSS is used, donor skin can be spared, and the mesh ratio for autografts needed for coverage of the remaining, not-covered burn could be reduced to 1:2 or less. Reduced mesh ratio autografts guaranteed faster healing and reduced scarring [52].

TESE is a tissue-engineered skin equivalent developed by Takami et al. It comprises autologous cultured keratinocytes, fibroblasts, and a decellularized allogeneic dermis and requires three weeks of processing. After this time, it was transplanted to the third-degree burn wounds. The authors observed 96% of graft survival. TESE’s histological characteristics are similar to normal human STSGS. Therefore, it can be used for permanent repair of full-thickness skin defects [53]. Clinical applications of autologous keratinocytes and fibroblasts in burns are summarized in Table 1.
Table 1. Clinical applications of autologous keratinocytes, products based on autologous keratinocyte and autologous engineered skin in burns (NA—not available, CEA—cultured epithelial autograft, AT—active treatment, CT—control group, TBSA—total body surface area, CEA/A—cadaver allograft followed by placement of CEA onto an allogerm base, STSG—split-thickness skin graft, TESE—tissue-engineered skin equivalent, CSS—cultured skin substitutes).

| Therapy Compared to | Route and Number of Administrations | Burn Characteristics | Follow Up | # of Patients | Age Range [Years] | Result | Author | Year |
|---------------------|-------------------------------------|----------------------|-----------|---------------|------------------|---------|--------|------|
| Autologous keratinocytes |                                     |                      |           |               |                  |         |        |      |
| cultured epithelium | NA                                  | grafts placed on a wound bed | major burns | NA            | 2                | 5–6     | permanent epidermis generation | Gallico et al. [24] | 1984 |
| cultured autologous epidermis | NA                  | NA                   | second-and third-degree burn wounds | up to 4 years | 17              | NA      | less hypertrophic scar formation | Teepe et al. [25] | 1990 |
| CEA                  | NA                                  | NA                   | NA        | NA            | 104              | NA      | final take rate of about 60% | Odessey et al. [26] | 1992 |
| cultured autologous keratinocytes | without graft | grafts | massive burns | NA | 64 (22–AT, 42–CT) | NA | mortality rate reduced from 48 to 14% | Munster et al. [27] | 1996 |
| sole-derived CEA     | Axilla-; groin- or foreskin-derived CEA | grafts | full-thickness burn wounds or giant congenital nevi | 3,5 years | 12              | 0–17 | re-expression of K9 after grafting on muscle fascia | Compton et al. [28] | 1998 |
| CEA/CellSpray/ CEA + CellSpray | NA | application to the wound bed | burns > 50% TBSA | NA | 62              | 30–49 | reduction on surgical intervention and total length of stay in hospital | Wood et al. [21] | 2006 |
| CEA/A               | NA                                  | application to the wound bed | large burns | 3–90 months | 88                | 0.5–73 | the mean final take rate 72.7% | Sood et al. [22] | 2010 |
| CEA                 | NA                                  | application to the wound bed | burns | NA | 63                | 2–70 | good outcome associated with young age and low number of infectious complications | Cirodde et al. [34] | 2011 |
| Therapy | Compared to | Route and Number of Administrations | Burn Characteristics | Follow Up | # of Patients | Age Range [Years] | Result                                                                 | Author | Year |
|---------|-------------|-------------------------------------|----------------------|-----------|---------------|-----------------|----------------------------------------------------------------------|--------|------|
| STSG + cultured autologous keratinocytes alone, STSG alone | application to the wound bed | full-thickness skin burn, 55–65% TBSA | NA | 20 | 4–12 | accelerated wound closure, better esthetical results | Chrapusta et al. [30] | 2014 |
| CEA | non-CEA | mean 2,1 applications to the wound bed | burns; 60–80% of the TBSA | NA | 177 (CEA: 96; non-CEA: 81) | NA | improved survival | Kym et al. [33] | 2015 |
| CAE only and CAE after allogeneic cultured epidermis application | grafts, in extensive burns in combination with large meshed STSG (1:6–1:12) | STSG donor sites and deep second-degree burns | NA | 63 | 0.75–58 | increased surface of the epidermal barrier | Auxefans et al. [29] | 2015 |
| CEA with a wide split auto mesh graft or patch graft | 1 application | severe burns | NA | 5 | 13–28 | excellent epithelialization | Matsumura et al. [31] | 2016 |
| STSG + CEA | micrografting + CEA | grafts | severe burns | NA | STSG + CEA: 10; micrografting + CEA: 14 | NA | significantly lower average area amount of skin used in the micrografting group | Chua et al. [35] | 2018 |
| CEA + widely meshed STSG (meshing ratio 1:3)/ Cuono method/ CEA only | an average of 8 sheets of CEA | burns ≥ 35% TBSA | 12 months | 12 (32 sites) | 22–67 | combination of STSG and CEA increases wound closure and improves CEA take rate | Lo et al. [36] | 2019 |
| CEA | NA | NA | burns | NA | 954 | <1–>80 | increased survival rate when combined with STSG | Hickerson et al. [37] | 2019 |
| Therapy                  | Compared to | Route and Number of Administrations | Burn Characteristics | Follow Up | # of Patients | Age Range [Years] | Result                                      | Author                | Year  |
|-------------------------|-------------|-------------------------------------|----------------------|-----------|---------------|-------------------|---------------------------------------------|-----------------------|-------|
| Products based on autologous keratinocytes |             |                                     |                      |           |               |                   |                                             |                       |       |
| Epicel®                 | NA          | grafts                              | burns                | NA        | 30            | 2.5–70            | very high beneficial value in the management of burns > 60% TBSA | Carsin et al. [39]     | 2000  |
| ReCell®                 | skin grafts | spray                               | deep partial-thickness burns | 6 months  | 82            | NA                | ReCell® gives similar results and is less invasive than skin grafting | Gravante et al. [44]  | 2007  |
| Keraheal™               | NA          | spray; combined with 1:4–6 mesh graft | extensive burns      | 24 weeks  | 29            | 30–49             | CEA’s take rate 100% after 4 weeks; enhanced take rate of a wide meshed autograft | Yim et al. [41]       | 2011  |
| Keraheal™               | NA          | spray; combined with 6:1 mesh graft when burn over 40% TBSA | full-thickness skin wound, TBSA 30–70% | up to 39 months | 16           | 18–70             | CEA’s take 68% after 4 weeks, 90.0% after 8 weeks | Lee et al. [13]       | 2012  |
| Biobrane® with or without ReCell® |             | local standard treatment with surgery at 10 days | application to the wound bed | a pediatric partial-thickness scald injury | until 6 months post-burn | 13 (Biobrane® only-4; Biobrane® and ReCell®-5; CT-4) | Biobrane® only: 1.5–8.8; Biobrane® and ReCell®:0.8–1.8; CT: 2.5–7.1 | Wood et al. [45]      | 2012  |
| ReCell®                 | STSG        | spray                               | partial-thickness burns | 52 weeks  | 10            | NA                | decreased donor site size, comparable outcomes with MSTSG treatment | Sood et al. [47]      | 2015  |
Table 1. Cont.

| Therapy                                                                 | Compared to                | Route and Number of Administrations | Burn Characteristics            | Follow Up | # of Patients | Age Range [Years] | Result                                               | Author                          | Year   |
|------------------------------------------------------------------------|----------------------------|-------------------------------------|----------------------------------|-----------|---------------|-------------------|-----------------------------------------------------|---------------------------------|--------|
| JACE® CEA                                                             | NA                         | grafts                              | burns > 30% TBSA                 | 52 weeks  | 216           | 0–99              | increased survival rate                              | Matsumura et al. [50]            | 2016   |
| JACE® CEA on meshed 3:1 split-thickness dermis graft or meshed 6:1 split-thickness autograft | NA                         | application to the wound bed        | massive burns                    | NA        | 3             | 51–66             | almost all of the burn wounds had healed at 6 weeks after surgery | Hayashi et al. [48]              | 2018   |
| Autologous engineered skin                                            | NA                         | grafts                              | full-thickness burn wounds       | 4 weeks   | 4             | 20–53             | advance in the care of extensively burned patients  | Hansbrough et al. [51]           | 1989   |
| autologous TESE (cultured keratinocytes and fibroblasts)              | NA                         | sheet                               | third-degree burn wounds         | up to 9 months | 4 | 29–63 | appropriate for permanent repair of full-thickness skin defects | Takami et al. [53]              | 2004   |
| CSS (autologous cultured keratinocytes and fibroblasts)              | STSG                       | grafts, CSS were meshed at a ratio of 1:1.5 and applied weekly | full-thickness Burns             | 2 to 7 years in 9 patients | 40 | 0.6–17 | better pigmentation, less scarring; no differences in qualitative outcomes after 1 year | Boyce et al. [52]               | 2006   |
3.1.4. Allogeneic Keratinocytes

Hefton et al. observed that burn wounds grafted with cultured allogeneic epidermal cells healed within three days and remained healthy for the nine months of observation. Based on these findings, the authors stated that allografts might serve as alternative biological dressings, or grafts, for deep second-degree burn wounds. They accelerate healing and reduce the need for STSG [54]. The same conclusion was drawn by Madden et al. where cultured allogeneic epidermal cells gave similar results to the autografts in second-degree burns and were not successful in third-degree ones [55]. Faster epithelialization of the wounds was also confirmed by Rivas-Torres et al. Healing time was reduced by 37.8% when treated with cultured epidermal allografts. Moreover, the authors observed that allografted sites were less erythematous than skin grafts, which served as a treatment control [56]. Similar results were obtained after transplantation of frozen cultured human allogeneic epidermal sheets in deep and superficial partial-thickness burns. Alvarez-Diaz et al. observed that deep partial-thickness burns treated with cultured allogeneic epidermal sheets healed in an average of 5.6 days versus 12.2 days in the control group [57]. Cryopreserved cultured epidermal allografts in pediatric patients were studied by Yanaga et al. Not only early wound closure and prevention of hypertrophic scar formation but also the decrease in graft cell viability were observed. The sex-determining region Y (SRY) gene could be detected only for 2–4 weeks after cell transplantation [17]. It proves that allograft take is not permanent, and allogeneic cells are replaced by autologous keratinocytes. Haslik et al. analyzed the long-term results of dermal hand burns covered with cryopreserved allogeneic keratinocyte sheet grafts. The authors compared these keratinocytes to autologous STSG and observed no statistically significant differences. The use of allogeneic keratinocytes for the coverage is appropriate to preserve skin grafts for full-thickness areas. Because of high costs and qualified staff requirements, in the presence of sufficient donor sites, the usage of skin grafts for the application in hand burns should be the first choice of treatment [58].

On the other hand, 15 years retrospective study of Auxenfans et al. revealed that cultured allogeneic keratinocytes (CALloK) facilitate healing of STSG donor-sites as well as deep second-degree burns. CALloK secrets growth factors and cytokines stimulating the proliferation of host keratinocytes in both acute and chronic wounds. Due to the storage options and availability, they can serve as temporary coverage. Transplantation of CALloK in deep dermal burns when there is a lack of donor sites may replace the use of STSG [14]. There is a product—KeraHeal-Allo™—which was investigated in phase 1 and 2 clinical trials. It is a thermosensitive hydrogel-type allogeneic keratinocyte therapy (Biosolutions Co., Ltd) to promote the reepithelialization of deep 2nd degree burns. No significant adverse reactions have been observed yet [59]. Clinical applications of allogeneic keratinocytes in burns are summarized in Table 2.

3.1.5. Allogeneic Keratinocytes and Fibroblasts

Apligraf® is a living, bi-layered cell-based product approved by the US. Food and Drug Administration (FDA) to heal diabetic foot ulcers and venous leg ulcers [60]. The lower dermal layer combines bovine type 1 collagen and human fibroblasts, which produce additional matrix proteins. The upper epidermal layer is formed by promoting human keratinocytes. Apligraf® does not contain melanocytes, Langerhans’ cells, macrophages, lymphocytes, or other structures such as blood vessels, hair follicles, or sweat glands [61]. Waymack et al. placed Apligraf® over a meshed autologous STSG over excised burn wounds. There was no difference in taking autograft in the presence or absence of Apligraf®. On the other hand, they demonstrated the cosmetic and functional advantages of Apligraf® when applied over meshed autograft [62]. Hu et al. 2006 USA evaluated the persistence of Apligraf® by DNA detection. After four weeks, it could be found only in the minority of patients [63]. Another product consisting of allogeneic keratinocytes and fibroblasts is OrCel™. It is composed of a porous collagen sponge containing co-cultured allogeneic donor epidermal
keratinocytes and dermal fibroblasts from human neonatal foreskin tissue [64]. Still et al. compared Biobrane-L® dressing with OrCel™ in facilitating wound closure in burn patients. The authors demonstrated that wound healing is faster after OrCel™ treatment. They explained that this effect is due to the combination of collagen sponge and cytokines and growth factors produced by the proliferating keratinocyte and fibroblast. OrCel™ sites also exhibited reduced scarring [65]. Clinical applications of allogeneic keratinocytes and fibroblasts in burns are summarized in Table 2.
Table 2. Clinical use of allogeneic keratinocytes and fibroblasts in burns (NA—not available, AT—active treatment, CT—control group, DDB—deep partial-thickness burn wounds, STSG—split-thickness skin graft, CDS—cultured dermal substitute).

| Therapy                          | Control/Compared To | Route of Administration | Burn Characteristics                   | Follow Up | # of Patients | Age Range [Years] | Result                                                                 | Author            | Year  |
|---------------------------------|---------------------|-------------------------|----------------------------------------|-----------|---------------|------------------|----------------------------------------------------------------------|-------------------|-------|
| Allogeneic keratinocytes        |                     |                         |                                        |           |               |                  |                                                                     |                   |       |
| cultured epidermal cells        | NA                  | sheets                  | second-degree burn wounds              | 9 months  | 3             | 25–49            | accelerated healing and an excellent cosmetic result               | Hefton et al.     | 1983  |
| cultured allogeneic epidermal cells | NA            | sheets                  | the donor site, second-and third-degree burn wounds | NA        | 26            | 12–70            | poor growth of cells placed on full-thickness, or third-degree burns | Madden et al.     | 1986  |
|banked cultured human epidermal allografts | NA        | grafts                  | donor sites and DDB                 | 3 months  | donor site –10; DDB –10 | DDB: 12–32; donor site: 12–41; DDB: 12–32 | AT–reepithelialization in about 6.9 days, CT–in an average of 11.1 days. | Rivas-Torres et al. | 1996  |
| frozen cultured human allografts | side-by-side with skin donor sites | sheets                  | deep and superficial partial-thickness burns | NA        | 11            | NA               | faster complete re-epithelialization and reduced healing time       | Alvarez-Diaz et al. | 2000  |
| cryopreserved cultured epidermal allografts | non-grafted areas | grafts                  | DDB, split-thickness skin donor sites | 1–8 years (mean: 4.75 years) | DDB: 43, donor site –12 | DDB: 4–17; donor sites: 1–17 | suppressed scar formation in both DDB and split-thickness skin donor sites | Yanaga et al.     | 2001  |
| allogeneic keratinocytes         | split skin grafts   | sheets                  | deep dermal hand burns               | AT–mean 24,8 months; CT–mean 22 months | 16 hands–AT; 17 hands–CT | 16–80            | no statistical significant differences                               | Haslik et al.     | 2010  |
| cultured allogeneic keratinocytes | NA                  | sheets                  | STSG donor sites and deep second-degree burn wounds | NA        | donor sites–59, burns–11 | 1.8–87            | complete healing in 6.4–7 days.                                     | Auxenfans et al.  | 2014  |
Table 2. Cont.

| Therapy | Control/Compared To | Route of Administration | Burn Characteristics | Follow Up | # of Patients | Age Range [Years] | Result | Author Year |
|---------|---------------------|-------------------------|----------------------|-----------|---------------|-------------------|--------|-------------|
| Allogeneic keratinocytes and fibroblasts | | | | | | | | |
| meshed (1:1.5), unexpanded Apligraf® applied over meshed (≥ 2:1) expanded autograft | meshed (≥ 2:1) expanded autograft alone or meshed (≥ 2:1) expanded autograft covered by meshed (1.5:1) unexpanded allograf | sheets | burns | 24 | 38 | 3–78 | Apligraf® sites better than the control for 22 (58%) patients | Waymack et al. [62] 2000 |
| OrCel™ dressing Biobrane-L® applied to the site wound | donor sites | 6 | 82 | 1–88 | accelerated wound healing, reduced scarring | Still et al. [65] 2003 |
| Apligraf® or Apligraf® dermis only (without epidermis) | dressings only | sheets | partial-thickness wounds | 2 | 10 | 37.01–64.59 | 4-weeks persistence of donor DNA | Hu et al. [63] 2005 |
| Allogeneic fibroblasts | | | | | | | | |
| allogeneic CDS overextended auto-skin graft | applied repeatedly at intervals of 5–7 days on the auto-skin graft on the wound | deep burn wounds, necrotizing fasciitis | NA | 3 | 39–88 | successful take of mesh auto-skin graft and prompt epithelization | Kashiwa et al. [66] 2004 |
| alloskin over meshed STSG | side-by-side with petroleum jelly–impregnated gauze over meshed STSG | Applied on the wound | third-degree burn wounds | 1 year | 14 | NA | reduced healing time but no difference after 1-year follow up | Moravvej et al. [67] 2012 |
3.1.6. Allogeneic Fibroblasts

Cultured dermal substitute (CDS) is composed of fibroblasts seeded on a porous matrix of hyaluronic acid and collagen. Kashiwa et al. evaluated CDS as a biological dressing for highly extended mesh auto-skin grafting. When applied onto the 6-fold extended auto-skin graft, it produces growth factors and extracellular matrix components, promoting the tissue granulation and epithelialization of the skin [66]. Moravvej et al. cultured allogeneic fibroblasts on a combination of silicone, glycosaminoglycan, and autologous mesh grafts. The authors observed that allogeneic fibroblasts grafted on meshed STSG might be useful for third-degree burn wounds treatment. Furthermore, it requires less autologous skin, which is a valuable advantage in extensive burns. Healing time and scar formation compared to conventional therapy is reduced, but after 1-year, there were no differences between these two groups [67]. Clinical applications of allogeneic fibroblasts in burns are summarized in Table 2.

3.1.7. Mesenchymal Stem Cells

Rasulov et al. applied allogeneic fibroblast-like bone marrow mesenchymal stem cells (BMSCs) onto deep thermal burn surfaces. The high tempo of wound regeneration in the presence of active neoangiogenesis was observed [68]. Moreover, the regeneration of sweat glands after deep burns is a significant clinical problem. Sheng et al. used BMSCs to acquire the phenotype of sweat gland cells in vitro. Twelve months after successful cell transplantation, the recovery of perspiration function in all the BMSC transplanted areas was observed. The authors emphasized that the success of the sweat gland regeneration depends not only on BMSCs but also on the surgical technique. The cells need to be covered with a decellularized allogeneic dermal matrix with laser-punched holes, granulated autologous skin grafting, and with allogeneic skin [69]. In another study, autologous transplantation of BMSCs in association with STSG was proved to prevent the skin graft contraction when combined with the injection into the sites of STSG [70]. Mansilla et al. studied cadaveric BMSC in a patient suffering an extensive skin burn. After two courses of cell transplantation and too slow epithelialization, autologous meshed skin was grafted. The skin healed completely without retractions. Limited hair regrowth was observed in the areas of BMSCs transplantation [71]. A prospective comparative study to evaluate the regenerative potential of BMSCs, and umbilical cord blood-derived mesenchymal stem cells (UC-MSCs) versus conventional early excision and grafting was performed by Wael Abo-Elkhei et al. The authors observed a significant improvement of healing both in the BMSC and UC-MSC application, with no significant difference between treatments [72]. Clinical applications of mesenchymal stem cells in burns are summarized in Table 3.
Table 3. Clinical applications of mesenchymal stem cells in burns (CMSCs—cadaveric bone marrow mesenchymal stem cells, NA—not available, AMSG—autologous meshed skin grafting, FMSC—fibroblast-like bone marrow mesenchymal stem cells, SG—skin grafts, BMSCs—bone marrow mesenchymal stem cells, UC-MSCs—umbilical cord blood-derived mesenchymal stem cells, TBSA—total body surface area).

| Therapy Compared To | Route and Number of Administrations | Burn Characteristics | Follow Up | # of Patients | Age Range [Years] | Result | Author | Year |
|---------------------|-------------------------------------|----------------------|-----------|---------------|------------------|--------|--------|------|
| allogeneic FMSC     | transplantation on the surface of the wound; followed by SG | extensive skin burn | NA        | 1             | 45               | promoted and accelerated healing | Rasulov et al. [68] | 2005 |
| sweat gland-like cell derived from BMSCs | cells transplanted to the wound, covered with a decellularized allogeneic dermal matrix with numerous laser-punched holes, granulated autologous skin grafting, and allogeneic skin | burn scars devoid of perspiration function | NA        | 5             | 7–21             | recovery of perspiration function | Sheng et al. [69] | 2008 |
| autologous cultured BMSCs + skin graft | cell injection to the wound | extensive skin burn, | 2 years   | 1             | 19               | smaller risk of contraction of the skin graft | Xu et al. [70] | 2012 |
| CMSCs               | 2 applications of CMSCs followed by AMSG | deep skin burns      | 3 years   | 1             | 26               | almost no scar or deformity in the places treated with CMSCs | Mansilla et al. [71] | 2015 |
| BMSCs and UC-MSCs   | early excision and graft | cell injection to the wound | full thickness burn, 10–25% TBSA | 6 months | 60 | BMSC: 20–27; UC-MSC: 18–29; CT: 18–35 | reduced hospitalization time in both BMSC and UC-MSC group | Abo-Elkheir et al. [72] | 2017 |
3.2. Treatment of Radiation Burns with Cell Therapies

Successful soft tissue reconstruction and absence of necrotic tissue with no recurrence of the lesion at 8-month follow-up was reported by Bey et al. Both surgical procedures and BMSCs therapy were performed on a 32-year-old man with a severe radiation burn of skin and underlying tissues in 3 approaches. Standard thermal burn treatment included a dermal substitute graft, but no improvement was observed. The second approach was based on muscle flap surgery and three local MSC administrations. Lack of complete healing led to the third approach—two local BMSC administrations. It resulted in a stable reconstruction of the soft tissue and complete pain relief. After BMSCs administration, a decrease of blood C-reactive protein (CRP) levels was noted, leading to the conclusion that BMSCs have an anti-inflammatory effect and accelerate the healing process [73]. Portas et al. confirmed these results. They reported the use of human cadaveric BMSCs in a patient with a radiation-induced skin lesion. The patient received three BMSCs administrations, and after each application, the CRP level decreased significantly [74]. The combination of physical therapy, surgery and local administrations of autologous BMSCs was presented in a case report by Lataillade et al. After BMSCs transplantation, almost complete healing was achieved within a month [75].

Attempts have also been made to use Adipose-Derived Stem Cells (ADSCs) in burn wounds treatment. Akita et al. treated patients with chronic radiation injuries with ADSCs and basic fibroblast growth factor (bFGF) sprayed over the radiation burn. The artificial dermis served as a scaffold. One part of the ADSCs was injected in the wound bed and margins; the other was placed over the artificial dermis. After bFGF application on a debrided tissue, increased angiogenesis and wound healing was observed. Fully regenerated tissue was seen during the 1.5-year follow-up, proving that ADSCs can be used to successfully treat the radiated wounds [76]. Moreover, beneficial effects have been reported from the transplant of lipoaspirates containing adipose-derived stem cells into wounds caused by radiotherapy [77]. Recently, a new technique has been developed—wound treatment with the cryopreserved placental membrane (vLPM). vLPM contains an extracellular matrix, growth factors, endogenous neonatal MSCs, fibroblasts, and epithelial cells of the native tissue. Regulski et al. published a case report of a 73-year-old patient with radiation necrosis. Since the wound was not qualified for surgical closure, 12 courses of vLPM were applied. The complete closure of the wound was observed at day 98 [12]. Clinical applications of cell-based therapies in radiation burns are summarized in Table 4.
Table 4. Clinical applications of cell-based therapies in radiation burns (BMSCs—bone-marrow mesenchymal stem cells; BMNCs—bone marrow mononuclear cells, ADSCs—adipose-derived stem cells; rh-bFGF—human recombinant fibroblast growth factor; vLPM—lyopreserved placental membrane containing viable cells).

| Therapy                                                                 | Compared To                          | Route and Number of Administrations | Burn Characteristics                                                                 | Follow Up            | # of Patients | Age Range | Result                                                                                     | Author                          | Year |
|------------------------------------------------------------------------|--------------------------------------|-------------------------------------|--------------------------------------------------------------------------------------|----------------------|---------------|-----------|---------------------------------------------------------------------------------------------|---------------------------------|------|
| autologous lipoaspirates containing ADSCs from a healthy donor site    | NA                                   | repeated low-invasive computer-assisted injection in supraclavicular region, the anterior chest wall | progressive lesions after radiation therapy                                         | 12, 18 and 31 months | 20            | 37–71     | progressive regeneration, including neovessel formation and improved hydration; systematic improvement or remission of symptoms | Rigotti G et al. [77]           | 2005 |
| autologous BMSCs                                                       | NA                                   | subcutaneous and intramuscular administrations | radiation burn                                                                      | 11 months           | 1             | 27        | healing progression, significant therapeutic improvement                                  | Lataillade et al. [75]          | 2007 |
| autologous BMMNCs                                                      | NA                                   | intradermal administrations          | radiation burn                                                                      | 8 months            | 1             | 32        | progression of the healing process, complete pain collapse                                 | Bey et al. [73]                 | 2010 |
| autologous ADSCs, an angiogenic and mitogenic factor of rh-bFGF, and an artificial dermis | NA                                   | intradermal injections and soaked with the artificial dermis | radiation burn                                                                      | 1.5 years           | 1             | NA        | healed wound; the regenerated tissue developed maturely in 1.5 years                      | Akita et al. [76]               | 2010 |
| human cadaveric MSC                                                    | NA                                   | instilled around and within the lesion | radiation-induced skin lesion                                                       | NA                   | 1             | 66        | reduction of the inflammation process, skin quality, and vasculature improvement            | Portas et al. [74]              | 2016 |
| vLPM                                                                   | NA                                   | allograft; 12 applications           | radiation necrosis wound                                                              | 3 months            | 1             | 73        | wound closure in 98 days                                                                    | Regulski et al. [12]            | 2019 |
4. Summary and Perspectives

While there have been a number of reports published on cell therapy for wound healing, clinically available therapies are still limited. In the last decade, several literature reviews have discussed the implications of cell transplantation in burn treatment [11,15,78–83]. The objective of our study was to update these findings.

The gathered data of cell-based therapies applications in burns confirms encouraging results and alternatives to standard care. In general, scientific evidence suggests that all presented bioengineered skin substitutes are safe. However, each of the presented strategies has its limitations and disadvantages. Moreover, caveats inherent with the clinical evidence covered in this report include differences in techniques measuring wound healing time and closure, small study groups, no information on how the recipient’s general health affects cell transplant acceptance. It is also difficult to conclude because burns vary significantly in depth, size, and the causing factor.

According to a multicenter experience with the treatment of partial and full skin thickness burns, the cultured autologous and allogeneic epidermis can be frozen and remains viable if stored in a skin bank [18]. There is no doubt that in comparison to the STSG, the culturing, storage, and use of keratinocytes (most studied cells) is associated with higher costs and institutional demands. The beneficial effect of their use has been demonstrated in several publications on burns in children, facial burns, donor sites, and in combination with mesh autologous skin grafts [84]. Unfortunately, a perfect technique does not exist. Despite the significant advantage of immunological safety, there are challenges with CEAs due to the long-term culture, insufficient donor site for extensive burn, and possible infections, as well as the high cost of this technique [4].

The use of isolated keratinocytes may represent an alternative therapy to CEA. The culturing time is much shorter, and the transplanted cells are not differentiated so that they may proliferate in the recipient after transplantation [15]. Therefore, due to the storage options and availability, they can serve as temporary coverage. Allogeneic keratinocytes are free of Langerhans cells and leukocytes—cells expressing major histocompatibility complex (MHC) class II, which results in a low probability of transplant rejection. Allogeneic keratinocytes do not remain in the transplant permanently and are replaced with the recipient cells [85]. Moreover, the area of skin serving as a source of keratinocytes isolation is crucial due to the number of epidermal stem cells and their proliferation potential [86].

As reported by Yanaga et al., cryopreserved cultured epidermal allografts have several advantages such as availability, the possibility of repeated treatments, enhanced wound closure, and does not require a donor’s presence [17]. In the case of severe, extensive burns, allogeneic fibroblasts grafted on meshed STSG should be considered [67]. It might be a useful method for third-degree burn wounds treatment. Furthermore, it requires less autologous skin, which is a valuable advantage. Alternatively, allogeneic fibroblast-like bone marrow mesenchymal stem cells (BMSCs) should be applied. The high tempo of deep thermal burn wound regeneration in the presence of active neoangiogenesis was observed [68]. On the other hand, it should be kept in mind that in developing countries, synthetic skin substitutes are either not available or are very expensive.

Although there is currently no significant scientific evidence suggesting that fat transplantation in acute burn wounds facilitates wound healing and improves subsequent scars, this therapeutic approach should be mentioned as a further perspective. It was confirmed that in burns, fat helps modify scar tissue by increasing vascularity and new collagen formation and deposition [87]. Several studies reported improvements in skin texture, thickness, color, and patient satisfaction [88]. Moreover, autologous stem cells from the adipose tissue of surgically debrided burned skin seem to be a promising idea. Rodney K. Chan et al. isolated these cells and proved that they could differentiate into epithelial, dermal, and hypodermal layers [89]. According to the authors, these results indicate that stem cells isolated from debrided skin can be used as a single autologous cell source to develop a vascularized skin construct without culture or addition of exogenous growth factors. This technique may provide an alternative approach for cutaneous coverage after
extensive burn injuries. A very recent case study demonstrated that the adipose-derived stromal cells seeded onto a collagen-based matrix, Integra®DRT exhibit valuable properties that may improve post-excision wound healing and facilitate skin regeneration without scars [90]. Unfortunately, it is difficult to assess this method’s effectiveness and establish a consensus due to the small number of studies. However, there is still a lack of randomized controlled trials supporting the efficacy of fat and adipose stem cell transplantation in burns.

Additionally, randomized controlled trials on MSCs isolated from bone marrow and adipose tissue are necessary to determine if these therapies are effective. However, such studies are unlikely to be carried out on patients with extensive, deep burns because these burns are rare and usually involve complex clinical decisions using different therapies that may vary between patients. Therefore, randomized trials of patients with smaller burns are recommended, as these burns occur more frequently, and the collection of data from small study groups may be more manageable. Besides, these studies should be performed with the longest possible observation time to assess the long-term safety and efficacy of cell-based therapies.

Furthermore, other approaches not discussed here seem to have significant therapeutic potential, including epidermal stem cells from hair follicles, embryonic cells, or induced pluripotent stem cells; however, future clinical trials will determine their effectiveness.

5. Conclusions

Although much progress has been made to demonstrate cell therapies’ effectiveness in burns, there are still scientific and technical challenges that need to be solved to introduce cell therapies as a standard clinical practice. Further evidence, including clinical trials, as well as studies assessing cell graft take and survival, is needed to demonstrate the clinical efficacy and safety of cell therapies in burns. Furthermore, the cost-effectiveness balance for cell therapy products is also a challenge. Finally, there is a high demand to determine the fate of transplanted cells and the number and type of cells required to obtain the best clinical outcome, as well as the most effective delivery system. We hope that our review will create a basis for further clinical studies and experimental research.

Author Contributions: Conception and design, A.P.-D.-S.; literature review, A.P.-D.-S., M.O.K., A.M.C. and M.S.; drafting the article, A.P.-D.-S., M.O.K. and A.M.C.; critical revision for relevant intellectual content, A.P.-D.-S. and M.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References
1. World Health Organization. Violence and Injury Prevention. Burns. Available online: https://www.who.int/violence_injury_prevention/other_injury/burns/en/ (accessed on 23 November 2020).
2. Schaefer, T.J.; Tannan, S.C. Thermal Burns; StatPearls Publishing: Treasure Island, FL, USA, 2020.
3. Garden, O.J. Principles and Practice of Surgery; Churchill Livingstone Elsevier: London, UK, 2012; ISBN 9780702051166.
4. Li, Z.; Maitz, P. Cell therapy for severe burn wound healing. Burns Trauma 2018, 6. [CrossRef]
5. Arno, A.; Smith, A.H.; Blit, P.H.; Shehab, M.A.; Gauglitz, G.G.; Jeschke, M.G. Stem Cell Therapy: A New Treatment for Burns? Pharmaceuticals 2011, 4, 1355–1380. [CrossRef]
6. Church, D.; Elsayed, S.; Reid, O.; Winston, B.; Lindsay, R. Burn wound infections. Clin. Microbiol. Rev. 2006, 19, 403–434. [CrossRef]
7. Leclerc, T.; Thepenier, C.; Jault, P.; Bey, E.; Peltzer, J.; Touillas, M.; Duhamel, P.; Bargues, L.; Prat, M.; Bonderitter, M.; et al. Cell therapy of burns. Cell Prolif. 2011, 44, 48–54. [CrossRef]
8. Jaschke, W.; Schmuth, M.; Trianni, A.; Bartal, G. Radiation-Induced Skin Injuries to Patients: What the Interventional Radiologist Needs to Know. Cardiovasc. Intervent. Radiol. 2017, 40, 1131–1140. [CrossRef]
9. Barnett, G.C.; West, C.M.L.; Dunning, A.M.; Elliott, R.M.; Coles, C.E.; Pharoah, P.D.P.; Burnet, N.G. Normal tissue reactions to radiotherapy: Towards tailoring treatment dose by genotype. *Nat. Rev. Cancer* 2009, 9, 134–142. [CrossRef]

10. Jacobson, L.K.; Johnson, M.B.; Dedhia, R.D.; Niknam-Bienia, S.; Wong, A.K. Impaired wound healing after radiation therapy: A systematic review of pathogenesis and treatment. *Ipsos Open* 2017, 13, 92–105. [CrossRef]

11. Rodgers, K.; Jadhav, S.S. The application of mesenchymal stem cells to treat thermal and radiation burns. *Adv. Drug Deliv. Rev.* 2018, 123, 75–81. [CrossRef]

12. Regulski, M.J.; Danilkovich, A.; Saunders, M.C. Management of a chronic radiation necrosis wound with lyopreserved placental membrane containing viable cells. *Clin. Case Rep.* 2019, 7, 456–460. [CrossRef]

13. Lee, H. Outcomes of sprayed cultured epithelial autografts for full-thickness wounds: A single-centre experience. *Burns* 2012, 38, 931–936. [CrossRef]

14. Auxenfans, C.; Shipkov, H.; Bach, C.; Catherine, Z.; Lacroix, P.; Bertin-Maghit, M.; Damour, O.; Braye, F. Cultured allogenic keratinocytes for extensive burns: A retrospective study over 15 years. *Burns* 2014, 40, 82–88. [CrossRef]

15. Ter Horst, B.; Chouhan, G.; Moemeni, N.S.; Grover, L.M. Advances in keratinocyte delivery in burn wound care. *Adv. Drug Deliv. Rev.* 2018, 123, 18–32. [CrossRef]

16. Oryan, A.; Alemzadeh, E.; Moshiri, A. Burn wound healing: Present concepts, treatment strategies and future directions. *J. Wound Care* 2017, 26, 5–19. [CrossRef]

17. Yanaga, H.; Udoh, Y.; Yamauchi, T.; Yamamoto, M.; Kiyokawa, K.; Inoue, Y.; Tai, Y. Cryopreserved cultured epidermal allografts achieved early closure of wounds and reduced scar formation in deep partial-thickness burn wounds (DDB) and split-thickness skin donor sites of pediatric patients. *Burns* 2001, 27, 689–698. [CrossRef]

18. Hsieh, C.-S.; Schoung, J.-Y.; Huang, W.S.; Huang, T.T. Five years’ experience of the modified Meek technique in the management of extensive burns. *Burns* 2008, 34, 350–354. [CrossRef]

19. Domaszewska-Szostek, A.; Krzyżanowska, M.; Siemionow, M. Cell-Based Therapies for Chronic Wounds Tested in Clinical Studies: Review. *Ann. Plast. Surg.* 2019, 83, e96–e109. [CrossRef]

20. Pham, C.; Greenwood, J.; Cleland, H.; Woodruff, P.; Maddrick, G. Bioengineered skin substitutes for the management of burns: A systematic review. *Burns* 2007, 33, 946–957. [CrossRef]

21. Wood, F.M.; Kolybaba, M.L.; Allen, P. The use of cultured epithelial autograft in the treatment of major burn injuries: A critical review of the literature. *Burns* 2006, 32, 395–401. [CrossRef]

22. Sood, R.; Roggy, D.; Zieger, M.; Balledux, J.; Chaudhari, S.; Koumanis, D.J.; Mir, H.S.; Cohen, A.; Knipe, C.; Gabehart, K.; et al. Cultured epithelial autografts for coverage of large burn wounds in eighty-eight patients: The Indiana University experience. *J. Burn Care Res.* 2010, 31, 559–568. [CrossRef]

23. Fang, T.; Lineaweaver, W.C.; Sailes, F.C.; Kissner, C.; Zhang, F. Clinical application of cultured epithelial autografts on acellular dermal matrices in the treatment of extended burn injuries. *Ann. Plast. Surg.* 2014, 73, 509–515. [CrossRef]

24. Gallico, G.G.; O’Connor, N.E.; Compton, C.C.; Kehide, O.; Green, H. Permanent coverage of large burn wounds with autologous cultured human epithelium. *N. Engl. J. Med.* 1984, 311, 448–451. [CrossRef]

25. Teepe, R.G.; Kreis, R.W.; Koebrugge, E.J.; Kempenaar, J.A.; Vloemans, A.F.; Boxma, H.; Dokter, J.; Hermans, J.; Ponec, M. The use of cultured autologous epidermis in the treatment of extensive burn wounds. *J. Trauma* 1990, 30, 269–275. [CrossRef]

26. Odessey, R. Addendum: Multicenter experience with cultured epithelial autograft for treatment of burns. *J. Burn Care Rehabil.* 1992, 13, 174–180. [CrossRef]

27. Munster, A.M. Cultured skin for massive burns: A prospective, controlled trial. *Ann. Surg.* 1996, 224, 372–377. [CrossRef]

28. Compton, C.C.; Nadire, K.B.; Regauer, S.; Warland, G.; Landry, D.B.; Simon, M.; O’Connor, N.E.; Gallico, G.G. Cultured human sole-derived keratinocyte grafts re-express site-specific differentiation after transplantation. *Differentiation* 1998, 64, 45–53. [CrossRef]

29. Auxenfans, C.; Menet, V.; Catherine, Z.; Shipkov, H.; Lacroix, P.; Bertin-Maghit, M.; Damour, O.; Braye, F. Cultured autologous keratinocytes in the treatment of large and deep burns: A retrospective study over 15 years. *Burns* 2015, 41, 71–79. [CrossRef]

30. Chrapusta, A.; Nessler, M.B.; Drukala, J.; Bartoszewicz, M.; Madry, R. A comparative analysis of advanced techniques for skin reconstruction with autologous keratinocyte culture in severely burned children: Own experience. *Postep. Dermatol. Alergol.* 2014, 31, 164–169. [CrossRef]

31. Matsumura, H.; Harunari, N.; Ikeda, H. First experience using cultured epidermal autografts in Taiwan for burn victims of the Formosa Fun Coast Water Park explosion, as part of Japanese medical assistance. *Burns* 2016, 42, 697–703. [CrossRef]

32. Wood, F.M.; Kolybaba, M.L.; Allen, P. The use of cultured epithelial autograft in the treatment of major burn wounds: Eleven years of clinical experience. *Burns* 2006, 32, 538–544. [CrossRef]

33. Kym, D.; Yim, H.; Yoon, J.; Yang, H.-T.; Cho, Y.S.; Hur, J.; Chun, W.; Kim, J.-H. The application of cultured epithelial autografts improves survival in burns. *Wound Repair Regen.* 2015, 23, 340–344. [CrossRef]

34. Ciroddde, A.; Leclerc, T.; Jault, P.; Duhamel, P.; Lataillade, J.-J.; Bargues, L. Cultured epithelial autografts in massive burns: A single-center retrospective study with 63 patients. *Burns* 2011, 37, 964–972. [CrossRef]

35. Chua, A.W.C.; Khoo, Y.C.; Truong, T.T.H.; Woo, E.; Tan, B.K.; Chong, S.J. From skin allograft coverage to allograft–micrograft sandwich method: A retrospective review of severe burn patients who received conjunctive application of cultured epithelial autografts. *Burns* 2018, 44, 1302–1307. [CrossRef]
36. Lo, C.H.; Akbarzadeh, S.; McLean, C.; Ives, A.; Paul, E.; Brown, W.A.; Cleland, H. Wound healing after cultured epithelial autografting in patients with massive burn injury: A cohort study. *J. Plast. Reconstr. Aesthet. Surg.* 2019, 72, 427–437. [CrossRef]

37. Hickerson, W.L.; Remmers, A.E.; Recker, D.P. Twenty-five years experience and beyond with cultured epidermal autografts for coverage of large burn wounds in adult and pediatric patients, 1989–2015. *J. Burn Care Res.* 2019, 40, 157–165. [CrossRef]

38. Epicel (Cultured Epidermal Autografts) | FDA. Available online: https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/epicel-cultured-epidermal-autografts (accessed on 23 November 2020).

39. Carsin, H.; Ainaud, P.; Le Bever, H.; Rives, J.; Lakhe, A.; Stephanazzi, J.; Lambert, F.; Perrot, J. Cultured epithelial autografts in extensive burn coverage of severely traumatized patients: A five year single-center experience with 30 patients. *Burns* 2000, 26, 379–387. [CrossRef]

40. Biosolution Co., Ltd. Biosolution Co., Ltd.: A Leader in Cell-Based Biotechnology. Available online: https://www.mfds.go.kr/eng/brd/m_30/view.do?seq=71374/ (accessed on 27 November 2020).

41. Yim, H.; Yang, H.T.; Cho, Y.S.; Seo, C.H.; Lee, K.B.; Kwak, I.S.; Kim, D.; Hur, J.; Kim, J.H.; et al. Clinical study of cultured epithelial autografts in liquid suspension in severe burn patients. *Burns* 2011, 37, 1067–1071. [CrossRef]

42. RECELL System | Suspension of Spray-On Skin Cells. Available online: https://recellsystem.com/about-recell-system (accessed on 23 November 2020).

43. RECELL Autologous Cell Harvesting Device. Available online: https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/recell-autologous-cell-harvesting-device (accessed on 7 January 2021).

44. Gravante, G.; Di Fede, M.C.; Araco, A.; Grimaldi, M.; De Angelis, B.; Arpino, A.; Cervelli, V.; Montone, A. A randomized trial comparing ReCell system of epidermal cells delivery versus classic skin grafts for the treatment of deep partial thickness burns. *Burns* 2007, 33, 966–972. [CrossRef]

45. Wood, F.; Martin, L.; Lewis, D.; Rawlinns, J.; McWilliams, T.; Burrows, S.; Rea, S. A prospective randomised clinical pilot study to compare the effectiveness of Biobrane®synthetic wound dressing, with or without autologous cell suspension, to the local standard treatment regimen in paediatric scald injuries. *Burns* 2012, 38, 830–839. [CrossRef]

46. Smith David, J. Use of Biobrane in Wound Management. *J. Burn Care Rehabil.* 1995, 16, 317–320. [CrossRef]

47. Sood, R.; Roggy, D.E.; Zieger, M.J.; Nazim, M.; Hartman, B.C.; Gibbs, J.T. A comparative study of spray keratinocytes and autologous meshed split-thickness skin graft in the treatment of acute burn injuries. *Wounds Comp. Clin. Res. Pract.* 2015, 27, 31–40.

48. Hayashi, M.; Yoshitake, K.; Tokunaka, R.; Yoshida, Y.; Oshima, M.; Tatsuta, S.; Hamada, T.; Kamitomo, A.; Hamajima, A. Combination of dermed meshed grafts and cultured epithelial autograft for massive burns: Three case reports. *Medicine* 2018, 97, e13313. [CrossRef]

49. Yano, K.; Watanabe, N.; Tsuyuki, K.; Ikawa, T.; Kasanuki, H.; Yamato, M. Regulatory Approval for Autologous Human Cells and Tissue Products in the United States, the European Union, and Japan. *Regen. Ther.* 2014, 1, 45–56. [CrossRef]

50. Matsumura, H.; Matsushima, A.; Ueyama, M.; Kumagai, N. Application of the cultured epidermal autograft “JACE(R)” for treatment of severe burns: Results of a 6-year multicenter surveillance in Japan. *Burns* 2016, 42, 769–776. [CrossRef]

51. Hanksbrough, J.F.; Boyce, S.T.; Cooper, M.L.; Foreman, T.J. Burn Wound Closure with Cultured Autologous Keratinocytes and Fibroblasts Attached to a Collagen-Glycosaminoglycan Substrate. *JAMA* *J. Am. Med. Assoc.* 1989, 262, 2125. [CrossRef]

52. Boyce, S.T.; Kagan, R.J.; Greenhalgh, D.G.; Warner, P.; Yakuboff, K.P.; Palmieri, T.; Warden, G.D. Cultured skin substitutes reduce requirements for harvesting of skin autograft for closure of excised, full-thickness burns. *J. Trauma Inj. Infect. Crit. Care* 2006, 60, 821–829. [CrossRef]

53. Takami, Y.; Yamaguchi, R.; Ono, S.; Hyakusoku, H. Clinical application and histological properties of autologous tissue-engineered skin equivalents using an acellular dermal matrix. *J. Nippon Med. Sch.* 2014, 81, 356–363. [CrossRef]

54. Hefton, J.M.; Madden, M.R.; Finkelstein, J.L.; Shires, G.T. Grafting of burn patients with allografts of cultured epidermal cells. *Lancet* 1983, 3, 428–430. [CrossRef]

55. Madden, M.R.; Finkelstein, J.L.; Staiano-Coico, L.; Goodwin, C.W.; Shires, G.T.; Nolan, E.E.; Hefton, J.M. Grafting of cultured autologous epidermises on second- and third-degree burn wounds on 26 patients. *J. Trauma* 1986, 26, 955–962. [CrossRef]

56. Rivas-Torres, M.T.; Amato, D.; Arambula-Alvarez, H.; Kuri-Harcuch, W. Controlled clinical study of skin donor sites and deep partial-thickness burns treated with cultured epidermal allografts. *Plast. Reconstr. Surg.* 1996, 98, 279–287. [CrossRef]

57. Alvarez-Diaz, C.; Cuenc-Pardo, J.; Sosa-Serrano, A.; Juarez-Aguilar, E.; Marsch-Moreno, M.; Kuri-Harcuch, W. Controlled clinical study of deep partial-thickness burns treated with frozen cultured human allogeneic epidermal sheets. *J. Burn Care Rehabil.* 2000, 21, 291–299. [CrossRef]

58. Haslik, W.; Kamolz, L.-P.; Lumenta, D.B.; Hladik, M.; Beck, H.; Frey, M. The treatment of deep dermal hand burns: How do we achieve better results? Should we use autologous keratinocytes or skin grafts? *Burns* 2010, 36, 329–334. [CrossRef]

59. Yim, H.; Yang, H.T.; Cho, Y.S.; Kim, D.; Kim, J.H.; Chun, W.; Hur, J. A clinical trial designed to evaluate the safety and effectiveness of a thermosensitive hydrogel-type cultured epidermal allograft for deep second-degree burns. *Burns* 2014, 40. [CrossRef]

60. Organogenesis: Apligraf®—Product Information. Available online: https://organogenesis.com/advanced-wound-care/apligraf/product-information.html (accessed on 24 November 2020).

61. Product Details | Apligraf®. Available online: https://apligraf.com/product-details/ (accessed on 24 November 2020).

62. Waymack, P.; Duff, R.G.; Sabolinski, M. The effect of a tissue engineered bilayered living skin analog, over meshed split-thickness autografts on the healing of excised burn wounds. The Apligraf Burn Study Group. *Burns* 2000, 26. [CrossRef]
63. Hu, S.; Kirsner, R.S.; Falanga, V.; Phillips, T.; Eagleton, W.H. Evaluation of Apligraf persistence and basement membrane restoration in donor site wounds: A pilot study. Wound Repair Regen. 2006, 14, 427–433. [CrossRef]

64. Ågren, M. Wound Healing Biomaterials. Volume I, Therapies and Regeneration; Woodhead Publishing: Cambridge, UK, 2016; ISBN 9780081006054.

65. Still, J.; Glat, P.; Silverstein, P.; Griswold, J.; Mozingo, D. The use of a collagen sponge/living cell composite material to treat donor sites in burn patients. Burns 2003, 29, 837–841. [CrossRef]

66. Kashima, N.; Ito, O.; Ueda, T.; Kubo, K.; Matsu, H.; Kuroyanagi, Y. Treatment of full-thickness skin defect with comcomitant grafting of 6-fold extended mesh autod-skin and allogeneic cultured dermal substitute. Artif. Organs 2004, 28, 444–450. [CrossRef]

67. Moravvej, H.; Hormozi, A.K.; Hosseini, S.N.; Sorouri, R.; Mozafari, N.; Ghazisaiidi, M.R.; Rad, M.M.; Moghim, M.H.; Sadeghi, S.M.; Mirzadeh, H. Comparison of the application of allogeneic fibroblast and autologous mesh grafting with the conventional method in the treatment of third-degree burns. J. Burn Care Res. 2016, 37, e90–e95. [CrossRef]

68. Rasulov, M.F.; Vasil’chenkov, A.V.; Onishchenko, N.A.; Krasheninnikov, M.E.; Kravchenko, V.I.; Gorshenin, T.L.; Pidtsan, R.E.; Potapov, I.V. First experience in the use of bone marrow mesenchymal stem cells for the treatment of a patient with deep skin burns. Bull. Exp. Biol. Med. 2003, 139, 141–145. [CrossRef]

69. Sheng, Z.; Fu, X.; Cai, S.; Lei, Y.; Sun, T.; Bai, X.; Chen, M. Regeneration of functional sweat gland-like structures by transplanted differentiated bone marrow mesenchymal stem cells. Wound Repair Regen. 2009, 17, 427–435. [CrossRef]

70. Xu, Y.; Huang, S.; Fu, X. Autologous transplantation of bone marrow-derived mesenchymal stem cells: A promising therapeutic strategy for prevention of skin-graft contraction. Clin. Exp. Dermatol. 2012, 37, 497–500. [CrossRef]

71. Mansilla, E.; Marin, G.H.; Berges, M.; Scafatti, S.; Rivas, J.; Núñez, A.; Menville, M.; Lamonega, R.; Gardiner, C.; Drago, H.; et al. Cadaveric bone marrow mesenchymal stem cells: First experience treating a patient with large severe burns. Burns Trauma 2015, 3, 1–9. [CrossRef]

72. Abo-Ellkheir, W.; Hamza, F.; Elmofty, A.M.; Emam, A.; Abd-Moktader, M.; Elsheref, S.; Gabr, H. Role of cord blood and bone marrow mesenchymal stem cells in recent deep burn: A case-control prospective study. Am. J. Stem Cells 2017, 6, 23–35.

73. Bey, E.; Prat, M.; Duhamel, P.; Benderitter, M.; Brachet, M.; Trompier, F.; Battaglini, P.; Ernou, I.; Boutin, L.; Gourven, M.; et al. Emerging therapy for improving wound repair of severe radiation burns using local bone marrow-derived stem cell administrations. Wound Repair Regen. 2010, 18, 50–58. [CrossRef]

74. Portas, M.; Mansilla, E.; Drago, H.; Dubner, D.; Radl, A.; Coppola, A.; Di Giorgio, M. Use of human cadaveric mesenchymal stem cells for cell therapy of severe radiation-induced skin lesion: A case report. Radiat. Prot. Dosim. 2016, 171, 99–106. [CrossRef]

75. Latailade, J.J.; Doucet, C.; Bey, E.; Carsin, H.; Huet, C.; Clairand, I.; Bottollier-Depois, J.F.; Chapel, A.; Ernou, I.; Gourven, M.; et al. New approach to radiation burn treatment by dosimetry-guided surgery combined with autologous mesenchymal stem cell therapy. Regen. Med. 2007, 2, 785–794. [CrossRef]

76. Akita, S.; Akino, K.; Hirano, A.; Ohtsuru, A.; Yamashita, S. Noncultured autologous adipose-derived stem cells therapy for chronic radiation injury. Stem Cells Int. 2010, 2010, 532704. [CrossRef]

77. Rigotti, G.; Marchi, A.; Galliè, M.; Baroni, G.; Benati, D.; Krampera, M.; Pasini, A.; Sbarbati, A. Clinical treatment of radiotherapy tissue damage by lipoaspirate transplant: A healing process mediated by adipose-derived adult stem cells. Plast. Reconstr. Surg. 2007, 119, 1409–1422; discussion 1423–1424. [CrossRef]

78. Haubner, F.; Ohmann, E.; Pohl, F.; Strutz, J.; Gassner, H.G. Wound healing after radiation therapy: Review of the literature. Radiat. Oncol. 2012, 7, 162. [CrossRef]

79. Ghieh, F.; Jurjas, R.; Ibrahim, A.; Geagea, A.G.; Daouk, H.; El Baba, B.; Chams, S.; Matar, M.; Zein, W.; Jurjas, A. The Use of Stem Cells in Burn Wound Healing: A Review. Biomed Res. Int. 2015, 684084. [CrossRef]

80. Maranda, E.; Rodríguez-Menocal, L.; Badiavas, E. Role of Mesenchymal Stem Cells in Dermal Repair in Burns and Diabetic Wounds. Curr. Stem Cell Res. Ther. 2016, 12, 61–70. [CrossRef]

81. Karalashvili, L.; Mardaleishvili, K.; Uhrny, M.; Chakhanashvili, D.; Kakabadze, Z. Current condition and challenges in treatment of non-healing wound after radiation therapy (review). Georgian Med. News 2018, 280–281, 23–28.

82. Kucharzewski, M.; Rojczyk, E.; Wilemska-Kucharzewska, K.; Wilk, R.; Hudecki, J.; Los, M.J. Novel trends in application of stem cells in skin wound healing. Eur. J. Pharmacol. 2019, 843, 307–315. [CrossRef]

83. Lo, C.H.; Chong, E.; Akbarzadeh, S.; Brown, W.A.; Cleland, H. A systematic review: Current trends and take rates of cultured epithelial autografts in the treatment of patients with burn injuries. Wound Repair Regen. 2019, 27, 693–701. [CrossRef]

84. Shevchenko, R.V.; James, S.L.; James, S.E. A review of tissue-engineered skin bioconstructs available for skin reconstruction. J. R. Soc. Interface 2010, 7, 229–258. [CrossRef]

85. McHei, J.N.; Barrault, C.; Levard, G.; Morel, F.; Bernard, F.-X.; Lecron, J.-C. Epidermal healing in burns: Autologous keratinocyte transplantation as a standard procedure: Update and perspective. Plast. Reconstr. Surg. Glob. Open 2014, 2, e218. [CrossRef]

86. Kretzschmar, K.; Watt, F.M. Markers of epidermal stem cell subpopulations in adult mammalian skin. Cold Spring Harb. Perspect. Med. 2016, 4. [CrossRef]

87. Riyat, H.; Touil, L.L.; Briggs, M.; Shokrollahi, K. Autologous fat grafting for scars, healing and pain: A review. Scars Burns Heal. 2017, 3, 2059513117728200. [CrossRef]

88. Negenborn, V.L.; Groen, J.-W.; Smit, J.M.; Niessen, F.B.; Mullender, M.G. The Use of Autologous Fat Grafting for Treatment of Scar Tissue and Scar-Related Conditions: A Systematic Review. Plast. Reconstr. Surg. 2016, 137, 31e–43e. [CrossRef]
89. Chan, R.K.; Zamora, D.O.; Wrice, N.L.; Baer, D.G.; Renz, E.M.; Christy, R.J.; Natesan, S. Development of a Vascularized Skin Construct Using Adipose-Derived Stem Cells from Debrided Burned Skin. *Stem Cells Int.* 2012, 2012, 1–11. [CrossRef]

90. Piejko, M.; Radziun, K.; Bobis-Wozowicz, S.; Waligór ska, A.; Zimolag, E.; Nessler, M.; Chrapusta, A.; Madeja, Z.; Drukała, J. Adipose-derived stromal cells seeded on integra® dermal regeneration template improve post-burn wound reconstruction. *Bioengineering* 2020, 7, 67. [CrossRef]